BioSpace News Archive

Vaxxas holds an exclusive license from The University of Texas at Austin (UTA) to the SARS-CoV-2 spike subunit vaccine (HexaPro) for vaccination using a patch.

Cardiff Oncology, Inc. today announced that company management will present and participate in 1x1 investor meetings at the Jefferies London Healthcare Conference, which is taking place in London.

Syantra, a precision healthcare company changing the way cancer is detected and treated, will present findings from the IDBC Study at the 13th European Breast Cancer Conference, held in Barcelona, Spain from 16 -18 November 2022.

Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177 Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC).

Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces it has initiated its SIGHT-2 dose-finding Phase 2b study for its proprietary drug-eluting contact lens for glaucoma.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) (“Altamira” or the “Company”), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the International Archives of Allergy and Immunology (IAAI) has published a peer-reviewed article titled, “Efficacy and safety of a drug-free, barrier-forming nasal spray for allergic rhinitis: randomized, open-label, crossover noninferiority trial.”

Cancer gene therapy has gained popularity in the last few years due to its high success rates during clinical and preclinical trials.